Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice

Pharmaceutical Research

Volumn 30, Issue 4, 2013, Pages 932-950

  Silber, B Michael ^a,b   Rao, Satish ^a,b   Fife, Kimberly L ^a   Gallardo Godoy, Alejandra ^a   Renslo, Adam R ^a   Dalvie, Deepak K ^c   Giles, Kurt ^a,b   Freyman, Yevgeniy ^a   Elepano, Manuel ^a   Gever, Joel R ^a,b   Li, Zhe ^a,b   Jacobson, Matthew P ^a   Huang, Yong ^a   Benet, Leslie Z ^a   Prusiner, Stanley B ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d not available   (United States)

Author keywords

antiprion drugs; drug discovery; IND24; IND81; prion disease

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; IND 2; IND 22; IND 24; IND 26; IND 29; IND 33; IND 36; IND 38; IND 42; IND 43; IND 44; IND 46; IND 47; IND 48; IND 49; IND 52; IND 57; IND 64; IND 7; IND 74; IND 76; IND 78; IND 81; IND 82; IND 85; IND 86; IND 91; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPRION ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; FEMALE; HUMAN; LIVER MICROSOME; MEDIAN EFFECTIVE CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 84876489693     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0912-4     Document Type: Article

References (42)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136-44.
2. Weissmann C. Spongiform encephalopathies - the prion's progress. Nature. 1991;349:569-71.
3. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519-50.
4. Prusiner SB. Prions and neurodegenerative diseases. N Engl J Med. 1987;317:1571-81.
5. Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, Terwilliger JD, et al. Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature. 1989;338:342-5.
6. Alpers M, Gajdusek DC. Changing patterns of kuru: epidemiological changes in the period of increasing contact of the Fore people with western civilization. Am J Trop Med Hyg. 1965;14:852-79.
7. Prusiner SB. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med. 2001;344:1516-26.
8. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155-9.
9. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem. 2009;78:177-204.
10. DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR, Prusiner SB. Identification of prion amyloid filaments in scrapie-infected brain. Cell. 1985;41:221-35.
11. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307:262-5.
12. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14:504-6.
13. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. 2009;106:13010-5.
14. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci USA. 2009;106:9679-84.
15. Sydow A, Mandelkow EM. 'Prion-Like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. Neurodegener Dis. 2010;7:28-31.
16. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-98.
17. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem. 2006;281:13828-36.
18. Race RE, Fadness LH, Chesebro B. Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol. 1987;68:1391-9.
19. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol. 2003;77:10288-94.
20. Kocisko DA, Caughey B, Morrey JD, Race RE. Enhanced antiscrapie effect using combination drug treatment. Antimicrob Agents Chemother. 2006;50:3447-9.
21. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006;129:2241-65.
22. Sim VL, Caughey B. Recent advances in prion chemotherapeutics. Infect Disord Drug Targets. 2009;9:81-91.
23. Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98:9836-41.
24. May BCH, Witkop J, Sherrill J, Anderson MO, Madrid PB, Zorn JA, et al. Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorg Med Chem Lett. 2006;16:4913-6.
25. Kempster S, Bate C, Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. NeuroReport. 2007;18:479-82.
26. Kimata A, Nakagawa H, Ohyama R, Fukuuchi T, Ohta S, Doh-ura K, et al. New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation. J Med Chem. 2007;50:5053-6.
27. Thompson MJ, Borsenberger V, Louth JC, Judd KE, Chen B. Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease. J Med Chem. 2009;52:7503-11.
28. Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, Doh-ura K. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol. 2007;81:12889-98.
29. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol. 2001;75:3453-61.
30. Ghaemmaghami S, May BCH, Renslo AR, Prusiner SB. Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol. 2010;84:3408-12.
31. Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011;54:1010-21.
32. Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Johns Hopkins Adv Stud Med. 2002;2:126-34.
33. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44:79-86.
34. Jonen HG, Werringloer J, Prough RA, Estabrook RW. The reaction of phenylhydrazine with microsomal cytochrome P-450. Catalysis of heme modification. J Biol Chem. 1982;257:4404-11.
35. Ghaemmaghami S, Ullman J, Ahn M, St. Martin S, Prusiner SB. Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem. 2010;285:10415-23.
36. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350-9.
37. Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res. 1990;7:902-10.
38. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23:327-38.
39. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc; 1982.
40. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry. 2001;40:12112-22.
41. Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, et al. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci USA. 2003;100:4784-9.
42. Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog. 2009;5:e1000673.